We know DAA s work, so now what? Simplifying models of care to enhance the hepatitis C cascade
Globally, some 71 million people are chronically infected with hepatitis C virus (HCV).
Marginalized populations, particularly people who inject drugs (PWID), have low testing …
Marginalized populations, particularly people who inject drugs (PWID), have low testing …
Hepatitis C treatment as prevention: evidence, feasibility, and challenges
The advent of interferon-free direct-acting antiviral therapy for hepatitis C virus (HCV)
infection has heightened discussion of treatment as prevention. Rapid scale-up in many …
infection has heightened discussion of treatment as prevention. Rapid scale-up in many …
Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia
Abstract Background Hepatitis C virus (HCV) infection is endemic among people who inject
drugs (PWID) globally. Despite high prevalence, treatment uptake is low, with cumulative …
drugs (PWID) globally. Despite high prevalence, treatment uptake is low, with cumulative …
Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia
Background & Aims The World Health Organization (WHO) established targets to eliminate
hepatitis C virus (HCV) infection as a public health threat by 2030. Evidence that HCV …
hepatitis C virus (HCV) infection as a public health threat by 2030. Evidence that HCV …
Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
Australia was one of the first countries to introduce government-funded unrestricted access
to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However …
to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However …
Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland Injectors' Health Network
Background Integrated treatment and harm reduction services provide a unique opportunity
to facilitate direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV)-infected people …
to facilitate direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV)-infected people …
High response and re‐infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme
J Schulkind, B Stephens, F Ahmad… - Journal of viral …, 2019 - Wiley Online Library
To achieve WHO hepatitis C virus (HCV) elimination targets by 2030, mathematical models
suggest there needs to be significant scale‐up of treatment among people who inject drugs …
suggest there needs to be significant scale‐up of treatment among people who inject drugs …
Chronic hepatitis C burden and care cascade in Australia in the era of interferon‐based treatment
Abstract Background and Aim Interferon‐free direct‐acting antiviral regimens for hepatitis C
virus (HCV) infection have been recently available in Australia, beginning a new era in …
virus (HCV) infection have been recently available in Australia, beginning a new era in …
Primary care and hepatology Provider–Perceived barriers to and facilitators of hepatitis C treatment Candidacy and adherence
SS Rogal, R McCarthy, A Reid, KL Rodriguez… - Digestive diseases and …, 2017 - Springer
Background Provider perceptions regarding barriers to and facilitators of hepatitis C (HCV)
treatment initiation and adherence have not been fully evaluated in the interferon-free …
treatment initiation and adherence have not been fully evaluated in the interferon-free …
Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues
F Marcellin, P Roux, C Protopopescu… - Expert review of …, 2017 - Taylor & Francis
ABSTRACT Introduction: Patient-reported outcomes (PROs) play a key role in the evaluation
of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C (CHC). The main …
of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C (CHC). The main …